Answers are grounded in this paper and cite their sources.
Overall, GE-XR at 600 mg twice a day did not reduce alcohol consumption or craving in individuals with AUD. It is possible that, unlike the IR formulation of gabapentin, which showed efficacy in smaller Phase 2 trials at a higher dose, GE-XR is not effective in treating AUD, at least not at doses approved by the U.S. Food and Drug Administration for treating other medical conditions.
No takes yet. Share an insight, caveat, or question.
Falk et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: